Results 191 to 200 of about 152,115 (284)

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 333-350, June 2026.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Advancements in the utilization of immune checkpoint inhibitors for the treatment of gynecological tumors. [PDF]

Front Immunol
Su Z, Zhang X, Xu J, Shen Y.
europepmc   +1 more source

Conditional survival in glioblastoma: The evolution of prognostic factors over time

International Journal of Cancer, Volume 158, Issue 10, Page 2571-2580, 15 May 2026.
What's New? Neurooncologists rely on glioblastoma risk stratification systems for incorporating known disease‐ and patient‐specific factors at diagnosis. Although useful for general comparison and disease monitoring, these estimates are less informative for patients who survive beyond various time intervals post‐diagnosis.
Timothy Mueller, Flavio Vasella, Julia Velz, Stefanos Voglis, Kevin Akeret, Luis Padevit, Morton Schubert, Jonathan Weller, Sarah Brüningk, Elisabeth Rushing, Johannes Sarnthein, Dorothee Gramatzki, Levin Häni, Andreas Raabe, Anna M. Zeitlberger, Oliver Bozinov, Emilie Le Rhun, Michael Weller, Luca Regli, Marian C. Neidert   +19 more
wiley   +1 more source

Intra-arterial infusion of bevacizumab for the treatment of peritoneal metastatic high-grade renal cell carcinoma: a case report. [PDF]

Front Immunol
Jin S, Dai C, Dai X, Zhao P, Zhou B, Zhang J, Fang W.   +6 more
europepmc   +1 more source

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson, Menna Shamma, Upeka Senanayake, Shaimaa Sahmoud, Kathleen Duffin, Victoria Howard, David King, Ayesha Fathani, Blanche Lumb, Andrei Pobischan, Irum Latif Memon, Monzir Ahmed, Rhian Thomas, Gerard Millen, Yasmeen Alomari, Sucheta Vaidya, Lynley V. Marshall, Sally L. George, Ramya Ramanujachar, Juliet Gray, Paola Angelini   +20 more
wiley   +1 more source

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study. [PDF]

J Immunother Cancer
Perez-Gracia JL, Mellado B, Hansen AR, Alonso-Gordoa T, Gomez-Roca C, Løvendahl Eefsen R, Negrier S, Suárez C, Lee JL, Hussain A, Pedrazzoli P, Moreno V, Rodriguez-Vida A, Sosman JA, Waddell T, Bedke J, Park SH, Sznol M, Spychaj L, Andersson E, Julien-Laferriere A, Cheng WY, Watson C, Silva AP, Heichinger C, Staedler N, Sleiman N, Dejardin D, Boetsch C, Evers S, Vardar T, Ardeshir-Tandon C, Dorado Pérez J, Charo J, Keshelava N, Kraxner A, Teichgräber V, Powles T.   +37 more
europepmc   +1 more source

Modern Clinical Trials: Seamless Designs and Master Protocols

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Drug development is often inefficient, costly and lengthy, yet it is essential for evaluating the safety and efficacy of new interventions. Compared with other disease areas, this is particularly true for Phase II/III cancer clinical trials where many drug candidates fail to advance and reduced regulatory approvals are being seen ...
Abigail Burdon, Thomas Jaki, Xijin Chen, Pavel Mozgunov, Haiyan Zheng, Richard Baird   +5 more
wiley   +1 more source

Full-Thickness Skin Transplantation Combined with Negative-Pressure Wound Therapy for a Refractory Peristomal Large Skin Ulcer Caused by Mucocutaneous Separation: A Case Report. [PDF]

Surg Case Rep
Okita A, Watanabe T, Nakagawa M, Ogino K, Hashida S, Tsukuda K, Yokoyama N.   +6 more
europepmc   +1 more source

Paradoxical Efficacy With Rare Adverse Events: Sequential ALK Inhibitor Therapy in Lung Adenocarcinoma

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Anaplastic lymphoma kinase (ALK) inhibitors have markedly improved outcomes in ALK‐positive nonsmall‐cell lung cancer (NSCLC). While their efficacy is well documented, rare or organ‐specific toxicities remain underreported, limiting clinicians' ability to anticipate and manage adverse events during treatment or rechallenge with tyrosine kinase
Kang Xie, Nie Xu
wiley   +1 more source

IMpower151: is this the final blow to PD-(L)1 inhibitors in metastatic, <i>EGFR</i>-mutant non-small-cell lung cancer? [PDF]

J Thorac Dis
van Beusekom SAL, Smeenk MM, de Langen AJ.   +2 more
europepmc   +1 more source